AbCellera Results Presentation Deck
Q3 2022 BUSINESS UPDATE
COPYRIGHT © ABCELLERA
6
PRE-PARTNERED PROGRAMS. CREATING VALUE THROUGH TECHNOLOGY-DEVELOPMENT.
UNRIVALED ABILITY TO BREAK THE BARRIERS
OF CONVENTIONAL DRUG DISCOVERY.
T-Cell Engager Platform
Hundreds of diverse CD3-binding
antibodies to combine to create optimized
precision cancer therapies.
Clinically-validated OrthoMab™
bispecifics platform, to pair CD3-targeting
and tumor-targeting antibodies.
Internal validation of panel through work
on three well-recognized and
high-value targets.
GPCRs & lon Channels Platform
Clinically validated, membrane-protein
targets with large commercial potential that
have proven largely intractable using
traditional methods for antibody discovery.
Internal platform integrated across the best of
modern data science and biotechnology to
generate best-in-class candidates.View entire presentation